Skip to main content
SpringerLink
Log in

Histone Deacetylase Inhibitors in APL and Beyond

  • Chapter
Acute Promyelocytic Leukemia

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 313))

Abstract

In recent years the study of chemical modifications to chromatin and their effects on cellular processes has become increasingly important in the field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acharya MR, Figg WD (2004) Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. Cancer Biol Ther 3:719–720

    PubMed  CAS  Google Scholar 

  2. Adachi M, Zhang Y, Zhao X, Minami T, Kawamura R, Hinoda Y, Imai K (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10:3853–3862

    Article  PubMed  CAS  Google Scholar 

  3. Almenara J, Rosato R, Grant S (2002) Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16:1331–1343

    Article  PubMed  CAS  Google Scholar 

  4. Amin HM, Saeed S, Alkan S (2001) Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 115:287–297

    Article  PubMed  CAS  Google Scholar 

  5. Antequera F, Bird A (1993) Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 90:11995–11999

    Article  PubMed  CAS  Google Scholar 

  6. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S (2004) Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 259:249–66; discussion 266–268, 285–288

    PubMed  CAS  Google Scholar 

  7. Atmaca A, Maurer A, Heinzel T, Gottlicher M, Neumann A, Al-Batran SE, Martin E, Bartsch I, Knuth A, Jaeger E (2004) A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer. J Clin Oncol 23:Abstr 3169

    Google Scholar 

  8. Aviram A, Zimrah Y, Shaklai M, Nudelman A, Rephaeli A (1994) Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. Int J Cancer 56:906–909

    PubMed  CAS  Google Scholar 

  9. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243–1254

    Article  PubMed  CAS  Google Scholar 

  10. Batova A, Shao LE, Diccianni MB, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J (2002) The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100:3319–3324

    Article  PubMed  CAS  Google Scholar 

  11. Baylin S, Bestor TH (2002) Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1:299–305

    Article  PubMed  CAS  Google Scholar 

  12. Beck J, Fischer T, George D, Huber C, Calvo E, Atadja P, Peng B, Kwong C, Sharma S, Patnaik A (2005) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of ORAL LBH589B: a novel histone deacetylase (HDAC) inhibitor. J Clin Oncol 24:Abstr 3148

    Google Scholar 

  13. Beck J, Fischer T, Rowinsky E, Huber C, Mita M, Atadja P, Peng B, Kwong C, Dugan M, Patnaik A (2004) Phase I pharmacokinetic and pharmacodynamic study of LBH-589A: a novel histone deacetylase inhibitor. J Clin Oncol 23:Abstr 3025

    Google Scholar 

  14. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63:7089–7093

    PubMed  CAS  Google Scholar 

  15. Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9:2395–2402

    Article  PubMed  CAS  Google Scholar 

  16. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21

    Article  PubMed  CAS  Google Scholar 

  17. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL (2002) Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13:869–874

    Article  PubMed  CAS  Google Scholar 

  18. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601

    Article  PubMed  CAS  Google Scholar 

  19. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105:959–967

    Article  PubMed  CAS  Google Scholar 

  20. Cai R, Kwon P, Yan-Neale Y, Sambuccetti L, Fischer D, Cohen D (2001) Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation. Biochem Biophys Res Commun 283:445–453

    Article  PubMed  CAS  Google Scholar 

  21. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103–107

    Article  PubMed  CAS  Google Scholar 

  22. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ (2004) Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316–321

    Article  PubMed  CAS  Google Scholar 

  23. Camphausen K, Scott T, Sproull M, Tofilon PJ (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066–6071

    Article  PubMed  CAS  Google Scholar 

  24. Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105–113

    Article  PubMed  CAS  Google Scholar 

  25. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR (2001) Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562–568

    PubMed  CAS  Google Scholar 

  26. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047–3055

    PubMed  CAS  Google Scholar 

  27. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2:379–387

    PubMed  CAS  Google Scholar 

  28. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615–2622

    Article  PubMed  CAS  Google Scholar 

  29. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467–8476

    Article  PubMed  CAS  Google Scholar 

  30. Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z, Dejean A, Harel-Bellan A (2004) HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23:8777–8784

    Article  PubMed  CAS  Google Scholar 

  31. Chinnaiyan P, Varambally S, Tomlins S, Huang S, Chinnaiyan A, Harari P (2004) Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. J Clin Oncol 23:Abstr 3029

    Google Scholar 

  32. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92:1300–1304

    PubMed  CAS  Google Scholar 

  33. Choi KY, Ji YJ, Jee C, Kim do H, Ahnn J (2002) Characterization of CeHDA-7, a class II histone deacetylase interacting with MEF-2 in Caenorhabditis elegans. Biochem Biophys Res Commun 293:1295–1300

    Article  PubMed  CAS  Google Scholar 

  34. Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489–6496

    Article  PubMed  CAS  Google Scholar 

  35. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61:3591–3594

    PubMed  CAS  Google Scholar 

  36. Colombo R, Boggio R, Seiser C, Draetta GF, Chiocca S (2002) The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1. EMBO Rep 3:1062–1068

    Article  PubMed  CAS  Google Scholar 

  37. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, Miller WH Jr (2002) Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 100:2586–2596

    Article  PubMed  CAS  Google Scholar 

  38. Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184:1–16

    Article  PubMed  CAS  Google Scholar 

  39. Czubryt MP, McAnally J, Fishman GI, Olson EN (2003) Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 100:1711–1716

    Article  PubMed  CAS  Google Scholar 

  40. Dalla-Favera R, Migliazza A, Chang CC, Niu H, Pasqualucci L, Butler M, Shen Q, Cattoretti G (1999) Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol 246:257–263; discussion 263–265

    PubMed  CAS  Google Scholar 

  41. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM (1996) Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 93:13143–13147

    Article  PubMed  CAS  Google Scholar 

  42. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A (1998) Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549–2556

    Article  PubMed  CAS  Google Scholar 

  43. David G, Neptune MA, DePinho RA (2002) SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem 17:17

    Google Scholar 

  44. Davison K, Mann KK, Miller WH Jr (2002) Arsenic trioxide: mechanisms of action. Semin Hematol 39:3–7

    Article  PubMed  CAS  Google Scholar 

  45. De Nadal E, Zapater M, Alepuz PM, Sumoy L, Mas G, Posas F (2004) The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes. Nature 427:370–374

    Article  PubMed  CAS  Google Scholar 

  46. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749

    Article  PubMed  Google Scholar 

  47. Demary K, Wong L, Spanjaard RA (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163:103–107

    Article  PubMed  CAS  Google Scholar 

  48. Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR (2004) Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127:1078–1086

    Article  PubMed  CAS  Google Scholar 

  49. Denlinger CE, Rundall BK, Jones DR (2004) Proteasome inhibition sensitizes nonsmall cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128:740–748

    Article  PubMed  CAS  Google Scholar 

  50. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG, Verdin E (2003) HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18:687–698

    Article  PubMed  CAS  Google Scholar 

  51. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436

    Article  PubMed  CAS  Google Scholar 

  52. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D (1997) Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 94:10762–10767

    Article  PubMed  CAS  Google Scholar 

  53. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM, Albagli O (1998) The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26:4645–4651

    Article  PubMed  CAS  Google Scholar 

  54. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079–1082

    Article  PubMed  Google Scholar 

  55. DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD (1999) Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 13:1243–1253

    Article  PubMed  CAS  Google Scholar 

  56. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S (2004) The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3:1397–1402

    PubMed  CAS  Google Scholar 

  57. Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608–1619

    Article  PubMed  CAS  Google Scholar 

  58. Eberharter A, Becker PB (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3:224–229

    Article  PubMed  CAS  Google Scholar 

  59. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463

    Article  PubMed  CAS  Google Scholar 

  60. el-Beltagi HM, Martens AC, Lelieveld P, Haroun EA, Hagenbeek A (1993) Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells—preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res 53:3008–3014

    PubMed  CAS  Google Scholar 

  61. el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB (1991) High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A 88:3470–3474

    Article  PubMed  CAS  Google Scholar 

  62. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153

    Article  PubMed  CAS  Google Scholar 

  63. Ferreira R, Naguibneva I, Pritchard LL, Ait-Si-Ali S, Harel-Bellan A (2001) The Rb/chromatin connection and epigenetic control: opinion. Oncogene 20:3128–3133

    Article  PubMed  CAS  Google Scholar 

  64. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, Trogani N, Widmer R, Atadja P, Cohen D (2002) Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem 277:6656–6666

    Article  PubMed  CAS  Google Scholar 

  65. Fischer T, Patnaik A, Bhalla K, Beck J, Morganroth J, Laird GH, Sharma S, Scott JW, Dugan M, Giles F (2005) Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 24:Abstr 3106

    Google Scholar 

  66. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276:35826–35835

    Article  PubMed  CAS  Google Scholar 

  67. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9:45–57

    Article  PubMed  CAS  Google Scholar 

  68. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W, Verdin E (1999) A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem 274:11713–11720

    Article  PubMed  CAS  Google Scholar 

  69. Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172–183

    Article  PubMed  CAS  Google Scholar 

  70. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24:88–91

    Article  PubMed  CAS  Google Scholar 

  71. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A 98:87–92

    Article  PubMed  CAS  Google Scholar 

  72. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916–4921

    PubMed  CAS  Google Scholar 

  73. Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL (2003) Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14:193–202

    Article  PubMed  CAS  Google Scholar 

  74. Galasinski SC, Resing KA, Goodrich JA, Ahn NG (2002) Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem 277:19618–19626

    Article  PubMed  CAS  Google Scholar 

  75. Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277:25748–25755

    Article  PubMed  CAS  Google Scholar 

  76. Gao N, Dai Y, Rahmani M, Dent P, Grant S (2004) Contribution of disruption of the nuclear factor-kappa B pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 66:956–963

    Article  PubMed  CAS  Google Scholar 

  77. Garcia-Manero G, Cannalli AA, Wierda W, Cortes J, O’Brien S, Cupo A, Secrist JP, Davis J, Faderl S, Giles F, Chiao JH, Richon V, Issa JP (2003) Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS). Blood 102:254b

    Article  CAS  Google Scholar 

  78. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Yang H, Fiorentino J, Rosner G, Issa JP (2005) Results of a phase I/II study of the combination of 5-aza-2-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 24:Abstr 6544

    Google Scholar 

  79. Gelmon K, Tolcher A, Carducci M, Reid GK, Li Z, Kalita A, Callejas V, Longstreth J, Besterman JM, Siu LL (2005) Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. J Clin Oncol 24:Abstr 3147

    Google Scholar 

  80. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768–1776

    Article  PubMed  CAS  Google Scholar 

  81. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292–2300

    PubMed  CAS  Google Scholar 

  82. Giles F, Fischer T, Cortes J, Beck J, Ravandi F, Garcia-Manero G, Kantarjian H, Peng B, Rae P, Laird G, Sharma S, Dugan M, Albitar M, Bhalla K (2004) A phaseI/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hematalogic malignances. Blood 104:499a

    Google Scholar 

  83. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND, Hay RT (2003) P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11:1043–1054

    Article  PubMed  CAS  Google Scholar 

  84. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151–163

    PubMed  CAS  Google Scholar 

  85. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59:4392–4399

    PubMed  CAS  Google Scholar 

  86. Gore SD, Samid D, Weng LJ (1997) Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3:1755–1762

    PubMed  CAS  Google Scholar 

  87. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963–970

    PubMed  CAS  Google Scholar 

  88. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978

    Article  PubMed  CAS  Google Scholar 

  89. Graveley BR (2001) Alternative splicing: increasing diversity in the proteomic world. Trends Genet 17:100–107

    Article  PubMed  CAS  Google Scholar 

  90. Gray SG, Iglesias AH, Teh BT, Dangond F (2003) Modulation of splicing events in histone deacetylase 3 by various extracellular and signal transduction pathways. Gene Expr 11:13–21

    PubMed  CAS  Google Scholar 

  91. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17–31

    Article  PubMed  CAS  Google Scholar 

  92. Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 96:4868–4873

    Article  PubMed  CAS  Google Scholar 

  93. Grozinger CM, Schreiber SL (2000) Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A 97:7835–7840

    Article  PubMed  CAS  Google Scholar 

  94. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349–352

    Article  PubMed  CAS  Google Scholar 

  95. Guardiola AR, Yao TP (2002) Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277:3350–3356

    Article  PubMed  CAS  Google Scholar 

  96. Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21:6091–6101

    Article  PubMed  CAS  Google Scholar 

  97. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634–2642

    PubMed  CAS  Google Scholar 

  98. Hartman HB, Yu J, Alenghat T, Ishizuka T, Lazar MA (2005) The histone-binding code of nuclear receptor co-repressors matches the substrate specificity of histone deacetylase 3. EMBO Rep 6:445–451

    Article  PubMed  CAS  Google Scholar 

  99. He L, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6:1131–1141

    Article  PubMed  CAS  Google Scholar 

  100. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126–135

    Article  PubMed  CAS  Google Scholar 

  101. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321–1330

    Article  PubMed  CAS  Google Scholar 

  102. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579–12589

    Article  PubMed  CAS  Google Scholar 

  103. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102:8567–8572

    Article  PubMed  CAS  Google Scholar 

  104. Hobdy E, Murren J (2004) AN-9 (Titan). Curr Opin Investig Drugs 5:628–634

    PubMed  CAS  Google Scholar 

  105. Hong SH, David G, Wong CW, Dejean A, Privalsky ML (1997) SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:9028–9033

    Article  PubMed  CAS  Google Scholar 

  106. Hook SS, Orian A, Cowley SM, Eisenman RN (2002) Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci U S A 99:13425–13430

    Article  PubMed  CAS  Google Scholar 

  107. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, delos Frailes M, Perez P, Krawiec J, Winkler J, Jaye M (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720–728

    Article  PubMed  CAS  Google Scholar 

  108. Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, Zhao L, Xie JX, Shen ZX, Wang ZY (1987) All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl) 100:949–953

    PubMed  CAS  Google Scholar 

  109. Huang Y, Tan M, Gosink M, Wang KK, Sun Y (2002) Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res 62:2913–2922

    PubMed  CAS  Google Scholar 

  110. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458

    Article  PubMed  CAS  Google Scholar 

  111. Huo X, Zhang J (2005) Important roles of reversible acetylation in the function of hematopoietic transcription factors. J Cell Mol Med 9:103–112

    PubMed  CAS  Google Scholar 

  112. Huynh KD, Bardwell VJ (1998) The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17:2473–2484

    Article  PubMed  CAS  Google Scholar 

  113. Huynh KD, Fischle W, Verdin E, Bardwell VJ (2000) BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 14:1810–1823

    PubMed  CAS  Google Scholar 

  114. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11Suppl 2:S193–206

    Article  PubMed  CAS  Google Scholar 

  115. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S (2004) Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 23:1144–1154

    Article  PubMed  CAS  Google Scholar 

  116. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71–76

    Article  PubMed  CAS  Google Scholar 

  117. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988–993

    Article  PubMed  CAS  Google Scholar 

  118. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H, et al (1990) Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo) 43:1524–1532

    PubMed  CAS  Google Scholar 

  119. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753–763

    Article  PubMed  CAS  Google Scholar 

  120. Jepsen K, Rosenfeld MG (2002) Biological roles and mechanistic actions of corepressor complexes. J Cell Sci 115:689–698

    PubMed  CAS  Google Scholar 

  121. Jing Y, Xia L, Waxman S (2002) Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 100:1008–1013

    Article  PubMed  CAS  Google Scholar 

  122. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302:2141–2144

    Article  PubMed  CAS  Google Scholar 

  123. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187–191

    Article  PubMed  CAS  Google Scholar 

  124. Jose B, Okamura S, Kato T, Nishino N, Sumida Y, Yoshida M (2004) Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence. Bioorg Med Chem 12:1351–1356

    Article  PubMed  CAS  Google Scholar 

  125. Kalita A, Maroun C, Bonfils C, Gelmon K, Siu LL, Tolcher A, Carducci M, Besterman JM, Reid GK, Li Z (2005) Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL). J Clin Oncol 24:Abstr 9631

    Google Scholar 

  126. Kamashev D, Vitoux D, De The H (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199:1163–1174

    Article  PubMed  CAS  Google Scholar 

  127. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ (2003) Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 160:1017–1027

    Article  PubMed  CAS  Google Scholar 

  128. Kao HY, Lee CH, Komarov A, Han CC, Evans RM (2002) Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J Biol Chem 277:187–193

    Article  PubMed  CAS  Google Scholar 

  129. Kao HY, Verdel A, Tsai CC, Simon C, Juguilon H, Khochbin S (2001) Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem 276:47496–47507

    Article  PubMed  CAS  Google Scholar 

  130. Kato H, Tamamizu-Kato S, Shibasaki F (2004) Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279:41966–41974

    Article  PubMed  CAS  Google Scholar 

  131. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738

    Article  PubMed  CAS  Google Scholar 

  132. Kawai H, Li H, Avraham S, Jiang S, Avraham HK (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107:353–358

    Article  PubMed  CAS  Google Scholar 

  133. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177–186

    Article  PubMed  CAS  Google Scholar 

  134. Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, Macgregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic Acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931

    Article  PubMed  CAS  Google Scholar 

  135. Kelly WK, Richon VM, O’Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578–3588

    PubMed  CAS  Google Scholar 

  136. Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 5:66–70

    Article  PubMed  CAS  Google Scholar 

  137. Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125:156–161

    Article  PubMed  CAS  Google Scholar 

  138. Khorasanizadeh S (2004) Thenucleosome: from genomic organization to genomic regulation. Cell 116:259–272

    Article  PubMed  CAS  Google Scholar 

  139. Kim JH, Shin JH, Kim IH (2004) Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59:1174–1180

    Article  PubMed  CAS  Google Scholar 

  140. Kim JS, Jeung HK, Cheong JW, Maeng H, Lee ST, Hahn JS, Ko YW, Min YH (2004) Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br J Haematol 124:166–178

    Article  PubMed  CAS  Google Scholar 

  141. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291–7300

    PubMed  CAS  Google Scholar 

  142. Kirsh O, Seeler JS, Pichler A, Gast A, Muller S, Miska E, Mathieu M, Harel-Bellan A, Kouzarides T, Melchior F, Dejean A (2002) The SUMOE3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J 21:2682–2691

    Article  PubMed  CAS  Google Scholar 

  143. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T (2000) Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 108:696–702

    Article  PubMed  CAS  Google Scholar 

  144. Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G (2003) Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17:350–358

    Article  PubMed  CAS  Google Scholar 

  145. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H (2001) Cyclic hydroxamicacid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61:4459–4466

    PubMed  CAS  Google Scholar 

  146. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530

    Article  PubMed  CAS  Google Scholar 

  147. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ueda R, Saito H, Naoe T (2001) In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn J Cancer Res 92:529–536

    PubMed  CAS  Google Scholar 

  148. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Gottlicher M (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411–3420

    Article  PubMed  Google Scholar 

  149. Kruh J (1982) Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42:65–82

    PubMed  CAS  Google Scholar 

  150. Kurdistani SK, Grunstein M (2003) Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4:276–284

    Article  PubMed  CAS  Google Scholar 

  151. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC, Kroll DJ (2001) The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1:121–131

    PubMed  CAS  Google Scholar 

  152. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277:2073–2080

    Article  PubMed  CAS  Google Scholar 

  153. Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672–2681

    Article  PubMed  CAS  Google Scholar 

  154. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21:2383–2396

    Article  PubMed  CAS  Google Scholar 

  155. Lea MA, Tulsyan N (1995) Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 15:879–883

    PubMed  CAS  Google Scholar 

  156. Lee H, Rezai-Zadeh N, Seto E (2004) Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 24:765–773

    Article  PubMed  CAS  Google Scholar 

  157. Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S (2002) Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277:22045–22052

    Article  PubMed  CAS  Google Scholar 

  158. Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, Smith R, Michaelides MR, Davidsen SK, Glaser KB (2004) Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci 74:2693–2705

    Article  PubMed  CAS  Google Scholar 

  159. Licht JD (2001) AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660–5679

    Article  PubMed  CAS  Google Scholar 

  160. Lipinski MM, Jacks T (1999) The retinoblastoma gene family in differentiation and development. Oncogene 18:7873–7882

    Article  PubMed  CAS  Google Scholar 

  161. LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR 3rd, Corbett TH (1996) Preclinical antitumor activity of CI-994. Invest New Drugs 14:349–356

    Article  PubMed  CAS  Google Scholar 

  162. Lu J, McKinsey TA, Zhang CL, Olson EN (2000) Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 6:233–244

    Article  PubMed  CAS  Google Scholar 

  163. Lund AH, van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18:2315–2335

    Article  PubMed  CAS  Google Scholar 

  164. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377–381

    Article  PubMed  CAS  Google Scholar 

  165. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S (2004) The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64:2590–2600

    Article  PubMed  CAS  Google Scholar 

  166. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601–605

    Article  PubMed  CAS  Google Scholar 

  167. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48:3344–3353

    Article  PubMed  CAS  Google Scholar 

  168. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223–237

    Article  PubMed  CAS  Google Scholar 

  169. Marcus AI, Zhou J, O’Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65:3883–3893

    Article  PubMed  CAS  Google Scholar 

  170. Margueron R, Trojer P, Reinberg D (2005) The key to development: interpreting the histone code? Curr Opin Genet Dev 15:163–176

    Article  PubMed  CAS  Google Scholar 

  171. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ (2002) Aphase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2:325–332

    Article  PubMed  CAS  Google Scholar 

  172. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21:6820–6831

    Article  PubMed  CAS  Google Scholar 

  173. McKinsey TA, Zhang CL, Olson EN (2000) Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinasestimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci U S A 97:14400–14405

    Article  PubMed  CAS  Google Scholar 

  174. McKinsey TA, Zhang CL, Olson EN (2001) Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol 21:6312–6321

    Article  PubMed  CAS  Google Scholar 

  175. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, Kim KW (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300:241–246

    Article  PubMed  Google Scholar 

  176. Mikhailov A, Shinohara M, Rieder CL (2004) Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 166:517–526

    Article  PubMed  CAS  Google Scholar 

  177. Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, Howard BH, Ozato K (1997) A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci U S A 94:11295–11300

    Article  PubMed  CAS  Google Scholar 

  178. Mistry AR, Pedersen EW, Solomon E, Grimwade D (2003) The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 17:71–97

    Article  PubMed  Google Scholar 

  179. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101:540–545

    Article  PubMed  CAS  Google Scholar 

  180. Mongan NP, Gudas LJ (2005) Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 4:477–486

    PubMed  CAS  Google Scholar 

  181. Munster PN, Marchion DC, Bicaku E, Sullivan P, Beam C, Mahany J, Lush R, Sullivan DM, Daud A (2005) Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: a clinical and translational study. J Clin Oncol 24:Abstr 3084

    Google Scholar 

  182. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386–389

    Article  PubMed  CAS  Google Scholar 

  183. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77–84

    Article  PubMed  CAS  Google Scholar 

  184. Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W, Olson S (2003) Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 9:58–66

    PubMed  CAS  Google Scholar 

  185. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS (2004) Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10:1813–1825

    Article  PubMed  CAS  Google Scholar 

  186. Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JHt, Steiner F, Schrump DS (2003) Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent deathsignaling pathway. J Thorac Cardiovasc Surg 125:1132–1142

    Article  PubMed  CAS  Google Scholar 

  187. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (2000) Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol 58:27–36

    PubMed  CAS  Google Scholar 

  188. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63:5126–5135

    PubMed  CAS  Google Scholar 

  189. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236–3239

    Article  PubMed  CAS  Google Scholar 

  190. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:437–444

    Article  PubMed  CAS  Google Scholar 

  191. North BJ, Verdin E (2004) Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 5:224

    Article  PubMed  Google Scholar 

  192. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C (2005) The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131:385–394

    Article  PubMed  CAS  Google Scholar 

  193. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Bang YJ (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10:5271–5281

    Article  PubMed  CAS  Google Scholar 

  194. Parra M, Kasler H, McKinsey TA, Olson EN, Verdin E (2005) Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem 280:13762–13770

    Article  PubMed  CAS  Google Scholar 

  195. Pasqualucci L, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, Cattoretti G, Dalla-Favera R (2003) Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk Lymphoma 44Suppl 3:S5–12

    Article  PubMed  CAS  Google Scholar 

  196. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 8:2142–2148

    PubMed  CAS  Google Scholar 

  197. Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J (2004) Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 22:886–896

    Article  PubMed  CAS  Google Scholar 

  198. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102:3697–3702

    Article  PubMed  CAS  Google Scholar 

  199. Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839–3852

    Article  PubMed  CAS  Google Scholar 

  200. Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A (2003) The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 278:16059–16072

    Article  PubMed  CAS  Google Scholar 

  201. Pflum MK, Tong JK, Lane WS, Schreiber SL (2001) Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem 276:47733–47741

    Article  PubMed  CAS  Google Scholar 

  202. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741

    Article  PubMed  CAS  Google Scholar 

  203. Piekarz R, Frye R, Turner B, Wright J, Leonard J, Allen S, Bates S (2004) Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. J Clin Oncol 23:Abstr 3028

    Google Scholar 

  204. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865–2868

    Article  PubMed  CAS  Google Scholar 

  205. Piperno G, LeDizet M, Chang XJ (1987) Microtubules containing acetylated alphatubulin in mammalian cells in culture. J Cell Biol 104:289–302

    Article  PubMed  CAS  Google Scholar 

  206. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728

    PubMed  CAS  Google Scholar 

  207. Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A (2004) Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329–1335

    Article  PubMed  CAS  Google Scholar 

  208. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM (2001) Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19:1–11

    Article  PubMed  CAS  Google Scholar 

  209. Primeau M, Gagnon J, Momparler RL (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103:177–184

    Article  PubMed  CAS  Google Scholar 

  210. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64:6626–6634

    Article  PubMed  CAS  Google Scholar 

  211. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG (1999) Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80:1252–1258

    Article  PubMed  CAS  Google Scholar 

  212. Racanicchi S, Maccherani C, Liberatore C, Billi M, Gelmetti V, Panigada M, Rizzo G, Nervi C, Grignani F (2005) Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J 24:1232–1242

    Article  PubMed  CAS  Google Scholar 

  213. Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S (2005) Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol 67:1166–1176

    Article  PubMed  CAS  Google Scholar 

  214. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65:2422–2432

    Article  PubMed  CAS  Google Scholar 

  215. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420–8427

    PubMed  CAS  Google Scholar 

  216. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45:381–386

    Article  PubMed  Google Scholar 

  217. Remiszewski SW (2003) The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 10:2393–2402

    Article  PubMed  CAS  Google Scholar 

  218. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P (2003) N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46:4609–4624

    Article  PubMed  CAS  Google Scholar 

  219. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014–10019

    Article  PubMed  CAS  Google Scholar 

  220. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 93:5705–5708

    Article  PubMed  CAS  Google Scholar 

  221. Robyr D, Suka Y, Xenarios I, Kurdistani SK, Wang A, Suka N, Grunstein M (2002) Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell 109:437–446

    Article  PubMed  CAS  Google Scholar 

  222. Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, Hoelzer D, Atadja P, Ruthardt M, Ottmann OG (2004) Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89:419–426

    PubMed  CAS  Google Scholar 

  223. Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63:3637–3645

    PubMed  CAS  Google Scholar 

  224. Rosato RR, Almenara JA, Yu C, Grant S (2004) Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 65:571–581

    Article  PubMed  CAS  Google Scholar 

  225. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23:3906–3911

    Article  PubMed  CAS  Google Scholar 

  226. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98:10833–10838

    Article  PubMed  CAS  Google Scholar 

  227. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912–3922

    Article  PubMed  CAS  Google Scholar 

  228. Sakamoto S, Potla R, Larner AC (2004) Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon stimulated early response genes. J Biol Chem 279:40362–40367

    Article  PubMed  CAS  Google Scholar 

  229. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718–728

    PubMed  CAS  Google Scholar 

  230. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE (2000) P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817–825

    Article  PubMed  CAS  Google Scholar 

  231. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Roman J, Barragan E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237–1243

    Article  PubMed  CAS  Google Scholar 

  232. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S (2003) Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66:897–906

    Article  PubMed  CAS  Google Scholar 

  233. Sawa H, Murakami H, Ohshima Y, Murakami M, Yamazaki I, Tamura Y, Mima T, Satone A, Ide W, Hashimoto I, Kamada H (2002) Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 19:77–81

    Article  PubMed  CAS  Google Scholar 

  234. Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y (2002) Phase I study of sequential deoxyazacytidine/ depsipeptide infusion in patients with malignancies involving lungs or pleura. Clin Lung Cancer 4:186–192

    PubMed  CAS  Google Scholar 

  235. Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14:115–121

    Article  PubMed  CAS  Google Scholar 

  236. Seelig MH, Berger MR (1996) Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur J Cancer 32A:1968–1976

    Article  PubMed  CAS  Google Scholar 

  237. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, Khochbin S (2001) Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21:8035–8044

    Article  PubMed  CAS  Google Scholar 

  238. Sellers WR, Kaelin WG Jr (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15:3301–3312

    PubMed  CAS  Google Scholar 

  239. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199–212

    Article  PubMed  CAS  Google Scholar 

  240. Shaker S, Bernstein M, Momparler LF, Momparler RL (2003) Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27:437–444

    Article  PubMed  CAS  Google Scholar 

  241. Simone C, Stiegler P, Forcales SV, Bagella L, De Luca A, Sartorelli V, Giordano A, Puri PL (2004) Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene 23:2177–2187

    Article  PubMed  CAS  Google Scholar 

  242. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 12:1325–1334

    Article  PubMed  CAS  Google Scholar 

  243. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis 113:264–268

    Article  PubMed  CAS  Google Scholar 

  244. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF (2005) Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 23:99–109

    Article  PubMed  CAS  Google Scholar 

  245. Sparrow DB, Miska EA, Langley E, Reynaud-Deonauth S, Kotecha S, Towers N, Spohr G, Kouzarides T, Mohun TJ (1999) MEF-2 function is modified by a novel co-repressor, MITR. EMBO J 18:5085–5098

    Article  PubMed  CAS  Google Scholar 

  246. Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS (2005) Sequential 5-aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24:2386–2397

    Article  PubMed  CAS  Google Scholar 

  247. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41–45

    Article  PubMed  CAS  Google Scholar 

  248. Su GH, Sohn TA, Ryu B, Kern SE (2000) A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60:3137–3142

    PubMed  CAS  Google Scholar 

  249. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, Davie JR (2002) The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 277:35783–35786

    Article  PubMed  CAS  Google Scholar 

  250. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001–3003

    Article  PubMed  CAS  Google Scholar 

  251. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W (2000) Effect of trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 88:992–997

    Article  PubMed  CAS  Google Scholar 

  252. Szyf M, Pakneshan P, Rabbani SA (2004) DNA demethylation and cancer: therapeutic implications. Cancer Lett 211:133–143

    Article  PubMed  CAS  Google Scholar 

  253. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298–4302

    Article  PubMed  CAS  Google Scholar 

  254. Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408–411

    Article  PubMed  CAS  Google Scholar 

  255. Tenen DG, Hromas R, Licht JD, Zhang DE (1997) Transcription factors, normal myeloid development, and leukemia. Blood 90:489–519

    PubMed  CAS  Google Scholar 

  256. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54:1690–1694

    PubMed  CAS  Google Scholar 

  257. Tong JJ, Liu J, Bertos NR, Yang XJ (2002) Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res 30:1114–1123

    Article  PubMed  CAS  Google Scholar 

  258. Tsai SC, Seto E (2002) Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 277:31826–31833

    Article  PubMed  CAS  Google Scholar 

  259. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976) A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 29:1–6

    PubMed  CAS  Google Scholar 

  260. Turner BM (2000) Histone acetylation and an epigenetic code. Bioessays 22:836–845

    Article  PubMed  CAS  Google Scholar 

  261. Turner BM (2002) Cellular memory and the histone code. Cell 111:285–291

    Article  PubMed  CAS  Google Scholar 

  262. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M (1994) Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 58:1579–1583

    PubMed  CAS  Google Scholar 

  263. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ (2004) A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 15:1705–1711

    Article  PubMed  CAS  Google Scholar 

  264. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102:673–678

    Article  PubMed  CAS  Google Scholar 

  265. Vanhaecke T, Papeleu P, Elaut G, Rogiers V (2004) Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11:1629–1643

    PubMed  CAS  Google Scholar 

  266. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11:542–552

    Article  PubMed  CAS  Google Scholar 

  267. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24:8374–8385

    Article  PubMed  CAS  Google Scholar 

  268. Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M, Khochbin S (2000) Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol 10:747–749

    Article  PubMed  CAS  Google Scholar 

  269. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19:286–293

    Article  PubMed  CAS  Google Scholar 

  270. Vidal M, Gaber RF (1991) RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae. Mol Cell Biol 11:6317–6327

    PubMed  CAS  Google Scholar 

  271. Waltregny D, De Leval L, Glenisson W, Ly Tran S, North BJ, Bellahcene A, Weidle U, Verdin E, Castronovo V (2004) Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 165:553–564

    PubMed  CAS  Google Scholar 

  272. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A, Castronovo V (2005) Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 19:966–968

    PubMed  CAS  Google Scholar 

  273. Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th’ng J, Han J, Yang XJ (1999) HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 19:7816–7827

    PubMed  CAS  Google Scholar 

  274. Wang AH, Kruhlak MJ, Wu J, Bertos NR, Vezmar M, Posner BI, Bazett-Jones DP, Yang XJ (2000) Regulation of histone deacetylase 4 by binding of 14-3-3 proteins. Mol Cell Biol 20:6904–6912

    Article  PubMed  CAS  Google Scholar 

  275. Wang AH, Yang XJ (2001) Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol Cell Biol 21:5992–6005

    Article  PubMed  CAS  Google Scholar 

  276. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R (2005) Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11:3535–3542

    Article  PubMed  CAS  Google Scholar 

  277. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621–1625

    Article  PubMed  CAS  Google Scholar 

  278. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS (2001) Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24:151–161

    Article  CAS  Google Scholar 

  279. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y (2005) Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol Cell 18:483–490

    Article  PubMed  CAS  Google Scholar 

  280. Williams RJ (2001) Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 10:1571–1573

    Article  PubMed  CAS  Google Scholar 

  281. Wong CW, Privalsky ML (1998) Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem 273:27695–27702

    Article  PubMed  CAS  Google Scholar 

  282. Woronicz JD, Lina A, Calnan BJ, Szychowski S, Cheng L, Winoto A (1995) Regulation of the Nur77 orphan steroid receptor in activation-induced apoptosis. Mol Cell Biol 15:6364–6376

    PubMed  CAS  Google Scholar 

  283. Wu J, Grunstein M (2000) 25 years after the nucleosome model: chromatin modifications. Trends Biochem Sci 25:619–623

    Article  PubMed  CAS  Google Scholar 

  284. Yamagoe S, Kanno T, Kanno Y, Sasaki S, Siegel RM, Lenardo MJ, Humphrey G, Wang Y, Nakatani Y, Howard BH, Ozato K (2003) Interaction of histone acetylases and deacetylases in vivo. Mol Cell Biol 23:1025–1033

    Article  PubMed  CAS  Google Scholar 

  285. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29:739–748

    Article  PubMed  CAS  Google Scholar 

  286. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E (2002) Functional domains of histone deacetylase-3. J Biol Chem 277:9447–9454

    Article  PubMed  CAS  Google Scholar 

  287. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:747–750

    Article  PubMed  CAS  Google Scholar 

  288. Yoder JA, Walsh CP, Bestor TH (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13:335–340

    Article  PubMed  CAS  Google Scholar 

  289. Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423–430

    Article  PubMed  CAS  Google Scholar 

  290. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174–17179

    PubMed  CAS  Google Scholar 

  291. Yoshida M, Shimazu T, Matsuyama A (2003) Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog Cell Cycle Res 5:269–278

    PubMed  Google Scholar 

  292. Youn HD, Sun L, Prywes R, Liu JO (1999) Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. Science 286:790–793

    Article  PubMed  CAS  Google Scholar 

  293. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S (2003) Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63:2118–2126

    PubMed  CAS  Google Scholar 

  294. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765–3774

    Article  PubMed  CAS  Google Scholar 

  295. Yu C, Rahmani M, Dent P, Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295:555–566

    Article  PubMed  CAS  Google Scholar 

  296. Zelent A, Greaves M, Enver T (2004) Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23:4275–4283

    Article  PubMed  CAS  Google Scholar 

  297. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD (2001) Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 20:7186–7203

    Article  PubMed  CAS  Google Scholar 

  298. Zelent A, Petrie K, Chen Z, Lotan R, Lubbert M, Tallman MS, Ohno R, Degos L, Waxman S (2005) Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy. Cancer Res 65:1–7

    Article  Google Scholar 

  299. Zeremski M, Stricker JR, Fischer D, Zusman SB, Cohen D (2003) Histone deacetylase dHDAC4 is involved in segmentation of the Drosophila embryo and is regulated by gap and pair-rule genes. Genesis 35:31–38

    Article  PubMed  CAS  Google Scholar 

  300. Zgouras D, Becker U, Loitsch S, Stein J (2004) Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316:693–697

    Article  PubMed  CAS  Google Scholar 

  301. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479–488

    Article  PubMed  CAS  Google Scholar 

  302. Zhang CL, McKinsey TA, Olson EN (2001) The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis. Proc Natl Acad Sci U S A 98:7354–7359

    Article  PubMed  CAS  Google Scholar 

  303. Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, Seto E (2005) Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 19:827–839

    Article  PubMed  CAS  Google Scholar 

  304. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K (2004) Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl) amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110:301–308

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Haemato-Oncology, Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, UK

    K. Petrie, N. Prodromou & A. Zelent

Authors
  1. K. Petrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Prodromou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Zelent
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Sloan-Kettering-Institute, 1275 York Avenue, New York, New York, 10021, USA

    Pier Paolo Pandolfi MD, Ph.D.

  2. The Scripps Research Institute, 10550 North Torreye Pines Road, La Jolla, CA, 92037, USA

    Peter K. Vogt Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Petrie, K., Prodromou, N., Zelent, A. (2007). Histone Deacetylase Inhibitors in APL and Beyond. In: Pandolfi, P.P., Vogt, P.K. (eds) Acute Promyelocytic Leukemia. Current Topics in Microbiology and Immunology, vol 313. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34594-7_10

Download citation

Publish with us

Policies and ethics

Search

Navigation